article thumbnail

Increasing patient engagement with UK clinical trials

pharmaphorum

Pharma companies face many challenges when involving patients in the design of clinical trials – but doing so can have huge benefits further down the line, improving the sustainability and quality of research. Linking pharma with patients.

article thumbnail

Synthetic control arms in clinical trials: Making it happen

pharmaphorum

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. Can the combined potential of new AI technologies and real-world patient data hold the key to overcoming the challenges in clinical trial design that have historically led to trial failure?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

BioSpace Movers & Shakers, Dec. 18

The Pharma Data

SpringWorks Therapeutics — Badreddin Edris has been promoted from chief business officer to COO and Mary Smith, Mary Smith, currently senior vice president of Clinical Research and Development, has been promoted to chief development officer at SpringWorks. AB2 Bio – Swiss pharma company AB2 Bio Ltd.

article thumbnail

Patient involvement in trial design: looking to the future

pharmaphorum

That was the message from ‘The New Normal: Balancing the rapid evolution of trial design with patient need’ panel at the NIHR’s Clinical Research Network Virtual Event on Delivering Complex and Innovative Design (CID) Studies. Thankfully, many pharma companies seem to be gradually improving on this. Listening to patients.

Trials 132
article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

Lin has made several transitions throughout her career, from being a clinician at an academic center, to academic research, to heading business development in industry. However, within industry organizations such as large pharma companies, funding tends to differ at each stage of research and development.